Top

Published in:

01-06-2011 | Epidemiology

Two functional variations in 5′-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese

Authors: Xiaoxiang Chen, Jingmei Wang, Wenwen Guo, Xiufang Liu, Caixia Sun, Zhenming Cai, Yimei Fan, Yaping Wang

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Abstract

8-Hydroxy-2′-deoxyguanine (8-OHdG) is produced by the oxidative stress-induced damage in DNA, which could pair with adenine (A) during DNA replication, leading to G-T transversion mutations. Glycosylase hOGG1 can recognize and excise oxidized guanines from duplex DNA. This work aims to investigate the relationship between the functional variations in 5-untranslated region (5′-UTR) of hOGG1 gene and the risk of breast cancer. Genotypes were analyzed in 518 sporadic breast cancer patients and 777 health controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression. Risk-stratified subgroup analysis was performed to reveal the associations between the detected variations and the risk of characteristic breast cancer. In addition, immunohistochemistry was carried out to assess the functional effect of these variations on hOGG1gene expression. Five variations in 5′-UTR of hOGG1 gene are found in this study. Three of them, c.-18G>T, c.-23A>G, and c.-53G>C, are known single nucleotide polymorphisms, the other two, c.-45G>A and c.-63G>C, are rare variations. The frequency of c.-18G/T and c.-53G/C was significantly higher in breast cancer patients than those in healthy controls (P = 0.03, OR 2.01, 95% CI 1.04–3.90; and P = 0.01, OR 2.43, 95% CI 1.17–5.04, respectively). Both variations were especially prevalent in premenopausal status, and in the triple (estrogen receptor, progesterone receptor, and human epidermal growth factor Receptor 2) negative subgroups, respectively. Moreover, the variation of c.-18G>T could cause a reduced expression of hOGG1 gene.

Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta, GA

Yang L, Parkin DM, Ferlay J, Liandi L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14:243–250PubMedCrossRef

Wilson III DM, Bohr VA (2007) The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair 6(4):544–559. doi:10.1016/j.dnarep.2006.10.017 CrossRef

Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA (2009) Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30(1):2–10. doi:10.1093/carcin/bgn250 PubMedCrossRef

Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11:1513–1530PubMed

Rossner P Jr, Terry MB, Gammon MD, Zhang FF, Teitelbaum SL, Eng SM, Sagiv SK, Gaudet MM, Neugut AI, Santella RM (2006) OGG1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15(4):811–815. doi:10.1158/1055-9965 PubMedCrossRef

Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F, Di Gregorio A, Polidoro S, Saletta F, Ioannidis JP, Matullo G (2009) A field synopsis on low-penetrance variants in DNA repairs genes and cancer susceptibility. J Natl Cancer Inst 101(1):24–36. doi:10.1093/jnci/djn437 PubMed

Dongying Gu, Meilin W, Zhengdong Z, Jinfei C (2010) Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case-control studies. Breast Cancer Res Treat 122(2):527–531. doi:10.1007/s10549-009-0723-4 CrossRef

Ishida T, Takashima R, Fukayama M, Hamada C, Hippo Y, Fujii T, Moriyama S, Matsuba C, Nakahori Y, Morita H, Yazaki Y, Kodama T, Nishimura S, Aburatani H (1999) New DNA polymorphisms of human MMH/OGG1 gene: prevalence of one polymorphism among lung adenocarcinoma patients in Japanese. Int J Cancer 80(1):18–21. doi:10.1002/(SICI)1097-0215(19990105)80:1<18:AID-IJC4>3.0.CO;2-E PubMedCrossRef

10.

Kim JC, Ka H, Lee YM, Koo KH, Kim HC, Yu CS, Jang SJ, Kim YS, Lee HI, Lee KH (2007) MYH, OGG1, MTH1, and APC alterations involved in the colorectal tumorigenesis of Korean patients with multiple adenomas. Virchows Arch 450(3):311–319. doi:10.1007/s00428-006-0363-6 PubMedCrossRef

11.

Kondo S, Toyokuni S, Tanaka T, Hiai H, Onodera H, Kasai H, Imamura M (2000) Overexpression of the hOGG1 gene and high 8-hydroxy-2′-deoxyguanosine (8-OHdG) lyase activity in human colorectal carcinoma: regulation mechanism of the 8-OHdG level in DNA. Clin Cancer Res 6(4):1394–1400PubMed

12.

Kohno T, Shinmura K, Tosaka M, Tani M, Kim S-R, Sugimura H, Nohmi T, Kasai H, Yokota J (1998) Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 16(25):3219–3225PubMedCrossRef

13.

Smith L (2008) Post-transcriptional regulation of gene expression by alternative 5′-untranslated regions in carcinogenesis. Biochem Soc Trans 36:708–711. doi:10.1042/BST0360708 PubMedCrossRef

14.

Wang T, Chen Y-H, Hong H, Zeng Y, Zhang J, Lu J-P, Jeansonne B, Lu Q (2009) Increased nucleotide polymorphic changes in the 5′-untranslated region of δ-catenin (CTNND2) gene in prostate cancer. Oncogene 28(4):555–564. doi:10.1038/onc.2008.399 PubMedCrossRef

15.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Marc van de Vijver M, Wheeler TM, Hayes DF (2007) ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145PubMedCrossRef

16.

Li D, Zhang W, Zhu J, Chang P, Sahin A, Singletary E, Bondy M, Hazra T, Mitra S, Lau SS, Shen J, DiGiovanni J (2001) Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Mol Carcinog 31(4):214–223. doi:10.1002/mc.1056 PubMedCrossRef

17.

Bartkova J, Hořejší Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(14):864–870. doi:10.1038/nature03482 PubMedCrossRef

18.

Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28(5):739–745. doi:10.1016/j.molcel.2007.11.015 PubMedCrossRef

19.

Dhénaut A, Boiteux S, Radicella JP (2000) Characterization of the hOGG1 promoter and its expression during the cell cycle. Mutat Res 461(2):109–118. doi:10.1016/S0921-8777(00)00042-2 PubMed

20.

Benz1 CC, Yau C (2008) Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer 8:875–879. doi:10.1038/nrc2522

21.

Lee JA, Kim K-I, Bae JW, Jung Y-H, Hyonggin A, Lee ES (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123(1):177–187. doi:10.1007/s10549-010-0998-5 PubMedCrossRef

22.

Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20(1):40–46. doi:10.1097/GCO.0b013e3282f40de9 PubMedCrossRef

23.

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071–1082. doi:10.1007/s10552-009-9331-1 PubMedCrossRef

24.

Reliene R, Bishop AJ, Schiestl RH (2007) Involvement of homologous recombination in carcinogenesis. Adv Genet 58:67–87. doi:10.1016/S0065-2660(06)58003-4 PubMedCrossRef

25.

Reis-Filho JS, Tutt ANJ (2008) Triple negative tumours: a critical review. Histopathology 1(52):108–118. doi:10.1111/j.1365-2559.2007.02889.x

26.

Alli E, Sharma VB, Sunderesakumar P, Ford JM (2009) Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly (ADP-Ribose) polymerase. Cancer Res 69(15):3589–3596. doi:10.1158/0008-5472.CAN-08-4016 PubMedCrossRef

27.

Saha T, Rih JK, Roy Ra, Ballal R, Rosen EM (2010) Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 285(25):19092–19105. doi:10.1074/jbc.M110.104430 PubMedCrossRef

28.

Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352–1355. doi:10.1126/science.1140735 PubMedCrossRef

29.

Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMedCrossRef

Title: Two functional variations in 5′-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese
Authors: Xiaoxiang Chen
Jingmei Wang
Wenwen Guo
Xiufang Liu
Caixia Sun
Zhenming Cai
Yimei Fan
Yaping Wang
Publication date: 01-06-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1284-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer

CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world

GRB7 protein over-expression and clinical outcome in breast cancer

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer